Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Ovarian Neoplasms 5Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Glioblastoma 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Lung Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uveal Melanoma 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hypertension 1

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Extensive Stage Lung Small Cell Carcinoma × cediranib × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡